Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Retinal Biologics Industry?

The size of the retinal biologics market has experienced significant growth in the past few years. It is projected to increase from $25.17 billion in 2024 to $28.12 billion in 2025, boasting a compound annual growth rate (CAGR) of 11.7%. Factors attributed to this growth during the historical period include a rise in retinal disorders, an aging population, increased awareness and early diagnosis, advancements in healthcare infrastructure, and a rise in healthcare spending.

In the upcoming years, we can envisage a swift surge in the retinal biologics market size. The projected expansion is expected to hit “$43.55 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 11.6%. Various factors contributing to this uptrend during the prediction phase encompass the broadening of therapeutic implementations, precision medicine, burgeoning market evolution, an impressive biologics pipeline, joint ventures and associations, as well as government stewardship and backing. The anticipated trends during the forecast period comprises non-invasive delivery modalities, the application of real-world evidence, broadening indications, simplification of regulatory pathways, and patient-oriented outcomes.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11911&type=smp

What Forces Are Driving The Growth Of The Retinal Biologics Industry?

The escalation of diabetic eye disease is anticipated to fuel the expansion of the retinal biologics market. As a diabetes complication, diabetic eye disease endangers the eyes by resulting in vision loss and blindness for individuals with diabetes. Retinal biologics have the ability to offer more accurate and effective treatments, enabling earlier interventions and enhanced results in preventing vision loss from diabetic eye disease. For example, the Australian Bureau of Statistics, an Australian government agency, released data in December 2023 revealing that in 2022, diabetes affected 5.3% of the Australian population (approximately 1.3 million individuals), a significant increase from 3.3%. Consequently, the rising prevalence of diabetic eye disease is steering the growth of the retinal biologics market.

The retinal biologics market covered in this report is segmented –

1) By Drug Class: Vascular Endothelial Growth Factor (VEGF)-A Antagonist, Tumor Necrosis Factor (TNF)-A Inhibitor

2) By Indication: Macular Degeneration, Diabetic Retinopathy, Uveitis, Diabetic Macular Edema, Other Indications

3) By Distribution Channel: Hospitals, Pharmacies, Specialty Clinics, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Vascular Endothelial Growth Factor (VEGF)-A Antagonist: Monoclonal Antibodies, Small Molecule Inhibitors

2) By Tumor Necrosis Factor (TNF)-A Inhibitor: Monoclonal Antibodies, Fusion Proteins

What Are The Leading Trends And Opportunities In The Retinal Biologics Sector?

A rising trend in the retinal biologics market is product innovation. In order to bolster their foothold and gain a competitive edge, key companies in the market are emphasizing on the creation of innovative products. Take for example, F. Hoffmann-La Roche Ltd., a healthcare company from Switzerland. In May 2023, the company disclosed that the U.S. Food and Drug Administration had accepted their supplemental biologics license application (sBLA) for Vabysmo (faricimab), a treatment for macular edema following retinal vein occlusion (RVO). The acceptance came on the back of two Phase III trials, which demonstrated early and sustained visual enhancement with Vabysmo, reaching the primary endpoint of non-inferiority to aflibercept. Vabysmo is the pioneer bispecific antibody approved for ocular use in treating ‘wet’ age-related macular degeneration and diabetic macular edema. Additionally, follow-up studies revealed no instances of retinal blood vessel leakage in Vabysmo patients as opposed to those treated with aflibercept.

Who Are The Primary Players Operating Across The Global Retinal Biologics Market?

Major companies operating in the retinal biologics market include Regeneron Pharmaceuticals Inc., AbbVie Inc., MeiraGTx Limited, Oxurion NV, Novartis AG, Amgen Inc., Spark Therapeutics Inc., Bayer AG, Bausch Health Companies Inc., Merck & Co. Inc., Santen Pharmaceutical Co. Ltd., Pfizer Inc., Boehringer Ingelheim, Eyenovia Inc., EyePoint Pharmaceuticals Inc., Iveric Bio Inc., Kodiak Sciences Inc., Aerie Pharmaceuticals Inc., Alimera Sciences Inc., Ocular Therapeutix Inc., Acucela Inc., Clearside Biomedical Inc., Ophthotech Corporation, Xcovery Holdings, Athenex Inc., Fidia Farmaceutici S.p.A, Eton Pharmaceuticals Inc.

https://www.thebusinessresearchcompany.com/report/retinal-biologics-global-market-report

Which Region Offers The Most Growth Potential For The Retinal Biologics Market Through 2029?

North America was the largest region in the retinal biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11911&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model